![Page 1: Mergers, Acquisitions & Alliances in Emerging Markets](https://reader035.vdocuments.us/reader035/viewer/2022062323/5681598a550346895dc6ccdd/html5/thumbnails/1.jpg)
Hale & Tempest
Mergers, Acquisitions & Alliances in Emerging Markets
Dr. Brian W Tempest
www.briantempest.com
Generics & Biosimilars, CpHI Conference Istanbul, Turkey
19 September 2012
![Page 2: Mergers, Acquisitions & Alliances in Emerging Markets](https://reader035.vdocuments.us/reader035/viewer/2022062323/5681598a550346895dc6ccdd/html5/thumbnails/2.jpg)
Hale & Tempest
Dr Brian Tempest advises Companies, Banks, High Net Worth Individuals and Investment Funds on their Strategy in the Emerging World based on his wide experience in China, Japan, South East Asia
and India where he has lived for the last decade.Brian has worked for Ranbaxy Laboratories since 1995 holding the position of Managing Director and Chief Executive Officer until 2005. He was then Chief Mentor and Non Executive Director until 2008 when he retired. He is one of the few westerners to have led a Sensex Nifty 50 Indian blue Chip MNC and as a result has a valuable insight into India. Brian has also worked for Glaxo as Regional Director
Far East and Regional Director Middle East & Africa from 1985 to 1992.Brian has worked in the Pharmaceutical Industry for the last 41 years and has managed Healthcare
businesses in North America, South America, Europe, Africa, Middle East, Australasia, China, Japan and India. He has also led many sessions at Investor Meetings held around the world.
He is now Independent Chairman of Religare Capital Markets, a Non Executive Director of Fortis Healthcare the leading Asian Healthcare Company, a Non Executive Director of SRL the largest Indian Diagnostic Company and a Non Executive Director of Glenmark Pharmaceuticals. He is a member of the SCRIP Global awards panel and is on the Editorial Board of the Journal of Generic Medicines. Brian speaks at global conferences and more information on these presentations can be
found on his website www.briantempest.com.Brian has a PhD in Polymer Chemistry from Lancaster University in 1971 and in 2009 he became Chairman of the Advisory Board for the Lancaster University Management School, UK. He is a
Fellow of the Royal Society of Medicine and a Fellow of the Royal Society of Chemistry and is a Chartered Chemist. He is now Chairman and Senior Partner of Hale & Tempest Co Ltd
![Page 3: Mergers, Acquisitions & Alliances in Emerging Markets](https://reader035.vdocuments.us/reader035/viewer/2022062323/5681598a550346895dc6ccdd/html5/thumbnails/3.jpg)
Hale & Tempest
Debt Impacting Global Healthcare
![Page 4: Mergers, Acquisitions & Alliances in Emerging Markets](https://reader035.vdocuments.us/reader035/viewer/2022062323/5681598a550346895dc6ccdd/html5/thumbnails/4.jpg)
Hale & Tempest
But Healthcare will expand faster in Asia
![Page 5: Mergers, Acquisitions & Alliances in Emerging Markets](https://reader035.vdocuments.us/reader035/viewer/2022062323/5681598a550346895dc6ccdd/html5/thumbnails/5.jpg)
Hale & Tempest
Pressures on Big Pharma
![Page 6: Mergers, Acquisitions & Alliances in Emerging Markets](https://reader035.vdocuments.us/reader035/viewer/2022062323/5681598a550346895dc6ccdd/html5/thumbnails/6.jpg)
Hale & Tempest
Pharma Business Model source: Pharmatimes World News April 2012
![Page 7: Mergers, Acquisitions & Alliances in Emerging Markets](https://reader035.vdocuments.us/reader035/viewer/2022062323/5681598a550346895dc6ccdd/html5/thumbnails/7.jpg)
Hale & Tempest
Is the Big Pharma Business Model Sustainable?
![Page 8: Mergers, Acquisitions & Alliances in Emerging Markets](https://reader035.vdocuments.us/reader035/viewer/2022062323/5681598a550346895dc6ccdd/html5/thumbnails/8.jpg)
Hale & Tempest
One of the largest R&D failures
“Nobody endured these lessons harder than Pfizer. The company built the world’s largest pharmaceutical research centre in Connecticut, USA , a 160 acre site with more than 5,000 employees at its peak and 2.7m sq ft of research space. But the only major drug to come out of the sprawling facility in the past 20 years was the smoking cessation treatment Chantix” Source; Pharmatimes February 2012
![Page 9: Mergers, Acquisitions & Alliances in Emerging Markets](https://reader035.vdocuments.us/reader035/viewer/2022062323/5681598a550346895dc6ccdd/html5/thumbnails/9.jpg)
Hale & Tempest
But Pharma R&D still needs Funding source: FT
![Page 10: Mergers, Acquisitions & Alliances in Emerging Markets](https://reader035.vdocuments.us/reader035/viewer/2022062323/5681598a550346895dc6ccdd/html5/thumbnails/10.jpg)
Hale & Tempest
So R&D Spend to 2018 is still growing source: Evaluate pharma 2012
![Page 11: Mergers, Acquisitions & Alliances in Emerging Markets](https://reader035.vdocuments.us/reader035/viewer/2022062323/5681598a550346895dc6ccdd/html5/thumbnails/11.jpg)
Hale & Tempest
Regulatory Challenges source: Pharmatimes World News Feb 2012
![Page 12: Mergers, Acquisitions & Alliances in Emerging Markets](https://reader035.vdocuments.us/reader035/viewer/2022062323/5681598a550346895dc6ccdd/html5/thumbnails/12.jpg)
Hale & Tempest
Big Pharma Corporate FinesSource: Daily Mail 3 July 2012
![Page 13: Mergers, Acquisitions & Alliances in Emerging Markets](https://reader035.vdocuments.us/reader035/viewer/2022062323/5681598a550346895dc6ccdd/html5/thumbnails/13.jpg)
Hale & Tempest
Big Pharma Corporate Fines source: FT August 7 2012
![Page 14: Mergers, Acquisitions & Alliances in Emerging Markets](https://reader035.vdocuments.us/reader035/viewer/2022062323/5681598a550346895dc6ccdd/html5/thumbnails/14.jpg)
Hale & Tempest
Merck – No 1 Layoffs in 2011 source FiercePharma
![Page 15: Mergers, Acquisitions & Alliances in Emerging Markets](https://reader035.vdocuments.us/reader035/viewer/2022062323/5681598a550346895dc6ccdd/html5/thumbnails/15.jpg)
Hale & Tempest
Will Big Pharma Change?
![Page 16: Mergers, Acquisitions & Alliances in Emerging Markets](https://reader035.vdocuments.us/reader035/viewer/2022062323/5681598a550346895dc6ccdd/html5/thumbnails/16.jpg)
Hale & Tempest
Big Pharma Changing Strategies
Share repurchase - Pfizer, Sanofi Aventis Shedding businesses – Pfizer $1.9b nutrition,
$3.6b animal health, £2.4b Capsugel Eye Care - Novartis & Alcon Consumer Healthcare – Sanofi Aventis, GSK Generics – Pfizer, Sanofi Aventis, AZ Pharmemerging – GSK, Abbott, Daichi Sankyo OTC – P&G with Teva entering India
![Page 17: Mergers, Acquisitions & Alliances in Emerging Markets](https://reader035.vdocuments.us/reader035/viewer/2022062323/5681598a550346895dc6ccdd/html5/thumbnails/17.jpg)
Hale & Tempest
Sanofi, GSK, Merck & Novartis cut Prices source: FT
![Page 18: Mergers, Acquisitions & Alliances in Emerging Markets](https://reader035.vdocuments.us/reader035/viewer/2022062323/5681598a550346895dc6ccdd/html5/thumbnails/18.jpg)
Hale & Tempest
Following the Asian Growth source: Bangkok Post 26 July 2012
![Page 19: Mergers, Acquisitions & Alliances in Emerging Markets](https://reader035.vdocuments.us/reader035/viewer/2022062323/5681598a550346895dc6ccdd/html5/thumbnails/19.jpg)
Hale & Tempest
>60% of GSK is a “non white pill” source: GSK Investor Presentation q4 2010, (vaccines, consumer, respiratory, derma)
![Page 20: Mergers, Acquisitions & Alliances in Emerging Markets](https://reader035.vdocuments.us/reader035/viewer/2022062323/5681598a550346895dc6ccdd/html5/thumbnails/20.jpg)
Hale & Tempest
Price Competition from Big Pharma at Jan 2012
ATORVASTATIN
- Ranbaxy in India 5 Rs per tablet
- Pfizer in NZ 1 Rs per tablet
CEPHALEXIN
- Ranbaxy in India
- GSK in India half price
![Page 21: Mergers, Acquisitions & Alliances in Emerging Markets](https://reader035.vdocuments.us/reader035/viewer/2022062323/5681598a550346895dc6ccdd/html5/thumbnails/21.jpg)
Hale & Tempest
Competition & Risk for
Generic Companies
![Page 22: Mergers, Acquisitions & Alliances in Emerging Markets](https://reader035.vdocuments.us/reader035/viewer/2022062323/5681598a550346895dc6ccdd/html5/thumbnails/22.jpg)
Hale & Tempest
Generics - Rising Risk & Competition
![Page 23: Mergers, Acquisitions & Alliances in Emerging Markets](https://reader035.vdocuments.us/reader035/viewer/2022062323/5681598a550346895dc6ccdd/html5/thumbnails/23.jpg)
Hale & Tempest
Contagious Price Erosion Across Markets source: Deutche Bank 22 may 2012
![Page 24: Mergers, Acquisitions & Alliances in Emerging Markets](https://reader035.vdocuments.us/reader035/viewer/2022062323/5681598a550346895dc6ccdd/html5/thumbnails/24.jpg)
Hale & Tempest
Patent Expiries to 2018 source: EvaluatePharma 2012
![Page 25: Mergers, Acquisitions & Alliances in Emerging Markets](https://reader035.vdocuments.us/reader035/viewer/2022062323/5681598a550346895dc6ccdd/html5/thumbnails/25.jpg)
Hale & Tempest
Global Generic Market Future Growth
![Page 26: Mergers, Acquisitions & Alliances in Emerging Markets](https://reader035.vdocuments.us/reader035/viewer/2022062323/5681598a550346895dc6ccdd/html5/thumbnails/26.jpg)
Hale & Tempest
Losing Control in the EU source: Teva June 2012
![Page 27: Mergers, Acquisitions & Alliances in Emerging Markets](https://reader035.vdocuments.us/reader035/viewer/2022062323/5681598a550346895dc6ccdd/html5/thumbnails/27.jpg)
Hale & Tempest
Stada focus on Russia Source: Stada
![Page 28: Mergers, Acquisitions & Alliances in Emerging Markets](https://reader035.vdocuments.us/reader035/viewer/2022062323/5681598a550346895dc6ccdd/html5/thumbnails/28.jpg)
Hale & Tempest
India Compulsory Licence source: ET 13 March 2012
![Page 29: Mergers, Acquisitions & Alliances in Emerging Markets](https://reader035.vdocuments.us/reader035/viewer/2022062323/5681598a550346895dc6ccdd/html5/thumbnails/29.jpg)
Hale & Tempest
New Measures allow Compulsory licences source: Chemistry World August 2012
![Page 30: Mergers, Acquisitions & Alliances in Emerging Markets](https://reader035.vdocuments.us/reader035/viewer/2022062323/5681598a550346895dc6ccdd/html5/thumbnails/30.jpg)
Hale & Tempest
Pending USA FDA ANDAs source: Deutsche Bank Jan 2012, 67%
![Page 31: Mergers, Acquisitions & Alliances in Emerging Markets](https://reader035.vdocuments.us/reader035/viewer/2022062323/5681598a550346895dc6ccdd/html5/thumbnails/31.jpg)
Hale & Tempest
ANDAs from Hisun, China in 2014/15
![Page 32: Mergers, Acquisitions & Alliances in Emerging Markets](https://reader035.vdocuments.us/reader035/viewer/2022062323/5681598a550346895dc6ccdd/html5/thumbnails/32.jpg)
Hale & Tempest
Indian Company Investment in Discovery source: Glenmark Annual Report 2012
![Page 33: Mergers, Acquisitions & Alliances in Emerging Markets](https://reader035.vdocuments.us/reader035/viewer/2022062323/5681598a550346895dc6ccdd/html5/thumbnails/33.jpg)
Hale & Tempest
Biosimilars
![Page 34: Mergers, Acquisitions & Alliances in Emerging Markets](https://reader035.vdocuments.us/reader035/viewer/2022062323/5681598a550346895dc6ccdd/html5/thumbnails/34.jpg)
Hale & Tempest
Deutsche Bank HK July 2010
![Page 35: Mergers, Acquisitions & Alliances in Emerging Markets](https://reader035.vdocuments.us/reader035/viewer/2022062323/5681598a550346895dc6ccdd/html5/thumbnails/35.jpg)
Hale & Tempest
Biotech Drugs where India has no DMF Source: JGM Volume 6 p333 sep 2009
![Page 36: Mergers, Acquisitions & Alliances in Emerging Markets](https://reader035.vdocuments.us/reader035/viewer/2022062323/5681598a550346895dc6ccdd/html5/thumbnails/36.jpg)
Hale & Tempest
Biosimilars from Indian Pharma Source: Deutsche Bank Jan 2012
![Page 37: Mergers, Acquisitions & Alliances in Emerging Markets](https://reader035.vdocuments.us/reader035/viewer/2022062323/5681598a550346895dc6ccdd/html5/thumbnails/37.jpg)
Hale & Tempest
How much is a Biosimilar worth?Source: Datamonitor
![Page 38: Mergers, Acquisitions & Alliances in Emerging Markets](https://reader035.vdocuments.us/reader035/viewer/2022062323/5681598a550346895dc6ccdd/html5/thumbnails/38.jpg)
Hale & Tempest
Sandoz Business Model -18 Year Payback source: Pharmacloud June 2012
![Page 39: Mergers, Acquisitions & Alliances in Emerging Markets](https://reader035.vdocuments.us/reader035/viewer/2022062323/5681598a550346895dc6ccdd/html5/thumbnails/39.jpg)
Hale & Tempest
Stada Licence In 2 Biosimilars source: Stada June 2012
![Page 40: Mergers, Acquisitions & Alliances in Emerging Markets](https://reader035.vdocuments.us/reader035/viewer/2022062323/5681598a550346895dc6ccdd/html5/thumbnails/40.jpg)
Hale & Tempest
Alliances – the New Faces
![Page 41: Mergers, Acquisitions & Alliances in Emerging Markets](https://reader035.vdocuments.us/reader035/viewer/2022062323/5681598a550346895dc6ccdd/html5/thumbnails/41.jpg)
Hale & Tempest
Rising Biosimilar Competition
Argentina Government is buying 14 cell lines from a Vancouver Company for local manufacture
In Thailand there are currently 19 EPOs
Celltrion, SK capacity is several 20,000L facilities with enough for the world’s supply
WHO is evaluating 2,000L capacity plants for Palivizumab in LA and Africa
![Page 42: Mergers, Acquisitions & Alliances in Emerging Markets](https://reader035.vdocuments.us/reader035/viewer/2022062323/5681598a550346895dc6ccdd/html5/thumbnails/42.jpg)
Hale & Tempest
Recent Biosimilar Deals
Cipla & Biomab, China $165m 12 products Richter & Stada – mABs, 2 products Celltrion, Korea -Hospira, Egis, Hikma, BB, etc Biocon & Mylan, USA, mABs Teva & Lonza, EU – limited range Biocon Idec & Samsung, Japan Watson & Amgen, USA Fuji Film & Kyowa Hakko Kirin DRL & Merck-Serono, Germany - mABs Actavis & Bioton, Poland - Insulin Pfizer & Hisun, China
![Page 43: Mergers, Acquisitions & Alliances in Emerging Markets](https://reader035.vdocuments.us/reader035/viewer/2022062323/5681598a550346895dc6ccdd/html5/thumbnails/43.jpg)
Hale & Tempest
Will the Tinibs takeover from the mABs?(Tinibs - Tyrosine Kinase Inhibitors -small molecules)
Axitinib, Pfizer, cancer Cediranib, AZ, cancer Pazopanib, GSK, cancer Regorafenib, Bayer, cancer Semaxanib, Sugen, cancer Sorafenib, Bayer(Nexavar),cancer Sunitinib, Pfizer, cancer Toceranib, Pfizer, cancer Vandetanib, AZ, cancer Tofactinib, Pfizer, RA
![Page 44: Mergers, Acquisitions & Alliances in Emerging Markets](https://reader035.vdocuments.us/reader035/viewer/2022062323/5681598a550346895dc6ccdd/html5/thumbnails/44.jpg)
Hale & Tempest
Biosimilars from China/India Source: New York Times 20 Sep 2011
![Page 45: Mergers, Acquisitions & Alliances in Emerging Markets](https://reader035.vdocuments.us/reader035/viewer/2022062323/5681598a550346895dc6ccdd/html5/thumbnails/45.jpg)
Hale & Tempest
A New World Order in Pharma is Coming